It is widely known that the gastrointestinal (GI) tract is prone to injury as a result of drug administration. While many assessments of the GI tract are often limited to measurements of transit time and observations of vomiting or diarrhea, VxP Pharma can develop methods and techniques that are capable of assessing specific changes in GI function at the membrane, cell, and whole animal levels.
At VxP Pharma, a complete range of in-vivo pharmacology services are available to support animal models, preclinical studies and/or clinical trials. Our exceptional team of scientists including toxicologists, pathologists, veterinary surgeons, regulatory specialists, and support personnel have designed and performed pharmacological testing on numerous individual study designs enabling our clients to quickly meet their product development goals. We can customize our in-vivo laboratory services to meet your unique objectives in a variety of animal models, and in order to provide efficient pharmacokinetic or toxicity data.
|Model||In-vivo model for assessment of potential of molecules/formulations to cause GI toxicity. May also be used for screening molecules for treatment of GI toxicities.|
|Test System||FOLFOX induced Mucositis in Wistar rat|
|Model||In-vitro model for digestive stimulants|
|Test System||Estimation of digestive enzyme activities using biochemical assays:
|Method||Evaluation of test compound’s effect on the activities of digestive enzymes of GI tract|
At VxP Pharma, we understand your needs and have the extensive experience working with the FDA, USDA, and EPA required to make your animal research projects a success. Specifically tailored, individual study designs enable our clients to meet their product development goals and facilitate world-wide regulatory approval. Our individualized approach to each study allows us to revise and shift directions based on your changing needs.
Our state-of-the-art labs are staffed by some of the best trained and most experienced subject matter experts in the field.